MovDisordV3, France, Analysis, bibRecord, 000222

Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study

Identifieur interne : 000222 ( France/Analysis ); précédent : 000221; suivant : 000223

Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study

Auteurs : Laurence Nègre-Pagès [France] ; Hélène Grandjean [France] ; Maryse Lapeyre-Mestre [France] ; Jean Louis Montastruc [France] ; Annie Fourrier [France] ; Jean Pierre Lépine [France] ; Olivier Rascol [France]

Source :

Movement Disorders [ 0885-3185 ] ; 2010-01-30.

RBID : ISTEX:D9D631DF5FDF4A4D8385A38A41862796FC1B8E65

Descripteurs français

Wicri :
- geographic : France.

English descriptors

KwdEn :
- Adult, Age Factors, Aged, Aged, 80 and over, Anti-Anxiety Agents (therapeutic use), Antidepressive Agents (therapeutic use), Anxiety (drug therapy), Anxiety (epidemiology), Anxiety (etiology), Anxiety (physiopathology), Cross-Sectional Studies, Depression (drug therapy), Depression (epidemiology), Depression (etiology), Depression (physiopathology), Female, France (epidemiology), Humans, Logistic Models, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Parkinson's disease, Prospective Studies, Questionnaires (standards), Severity of Illness Index, Sex Factors, antidepressant, anxiety, anxiolytic, depression.
MESH :
- chemical , therapeutic use : Anti-Anxiety Agents, Antidepressive Agents.
- geographic , epidemiology : France.
- drug therapy : Anxiety, Depression, Parkinson Disease.
- epidemiology : Anxiety, Depression, Parkinson Disease.
- etiology : Anxiety, Depression.
- physiopathology : Anxiety, Depression, Parkinson Disease.
- psychology : Parkinson Disease.
- standards : Questionnaires.
- Adult, Age Factors, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Logistic Models, Male, Middle Aged, Neuropsychological Tests, Prospective Studies, Severity of Illness Index, Sex Factors.

Abstract

Anxiety has been less extensively studied than depression in Parkinson's disease (PD). The DoPaMiP survey allowed assessing simultaneously anxiety and depressive symptoms in PD and comparing correlations of both symptoms with clinical and therapeutic features of the disease. Cross sectional survey conducted prospectively in 450 ambulatory nondemented PD patients and 98 patients with other disorders than PD. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), parkinsonism using the Unified Parkinson's Disease Rating Scale (UPDRS). Other clinical factors were measured using a structured standardized examination/questionnaire. The mean HADS‐A (anxiety) subscore was higher in PD patients than in the others (8.2 ± 3.9 vs. 6.5 ± 3.2, P < 10−4) as was the HADS‐D (depressive) subscore (6.6 ± 3.8 vs. 3.9 ± 3.2, P < 10−4). Patients with possible/probable anxious signs (HADS‐A ≥ 8) were more prevalent in PD (51% vs. 29%, P < 10−4) as were those with depressive symptoms (40% vs. 10%, P < 10−4). Conversely, anxiolytic and antidepressant medications consumption was not different between the 2 groups. Patients with anxious symptoms were more frequently female and younger than those without such symptoms, while those with depressive symptoms had more severe indices of parkinsonism, more comorbidities and lower cognitive function (Mini Mental State Exam). The logistic regression model revealed that patients with depressive symptoms received more frequently levodopa and less frequently a dopamine agonist. Anxiety and depressive symptoms were more frequent in PD patients than in medical control group. Both symptoms were commonly associated in the same PD patients, but were correlated with different clinical/therapeutic features, suggesting different underlying pathophysiological mechanisms. © 2009 Movement Disorder Society

Url:

https://api.istex.fr/document/D9D631DF5FDF4A4D8385A38A41862796FC1B8E65/fulltext/pdf

DOI: 10.1002/mds.22760

Affiliations:

Links to Exploration step

ISTEX:D9D631DF5FDF4A4D8385A38A41862796FC1B8E65

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study</title>
<author><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Nègre-Pagès">Laurence Nègre-Pagès</name>
</author>
<author><name sortKey="Grandjean, Helene" sort="Grandjean, Helene" uniqKey="Grandjean H" first="Hélène" last="Grandjean">Hélène Grandjean</name>
</author>
<author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name>
</author>
<author><name sortKey="Fourrier, Annie" sort="Fourrier, Annie" uniqKey="Fourrier A" first="Annie" last="Fourrier">Annie Fourrier</name>
</author>
<author><name sortKey="Lepine, Jean Pierre" sort="Lepine, Jean Pierre" uniqKey="Lepine J" first="Jean Pierre" last="Lépine">Jean Pierre Lépine</name>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D9D631DF5FDF4A4D8385A38A41862796FC1B8E65</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22760</idno>
<idno type="url">https://api.istex.fr/document/D9D631DF5FDF4A4D8385A38A41862796FC1B8E65/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000054</idno>
<idno type="wicri:Area/Istex/Curation">000054</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B26</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Negre Ages L:anxious:and:depressive</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19950403</idno>
<idno type="wicri:Area/PubMed/Corpus">001A71</idno>
<idno type="wicri:Area/PubMed/Curation">001A71</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001A37</idno>
<idno type="wicri:Area/Ncbi/Merge">002912</idno>
<idno type="wicri:Area/Ncbi/Curation">002912</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002912</idno>
<idno type="wicri:Area/Main/Merge">002283</idno>
<idno type="wicri:Area/Main/Curation">001E47</idno>
<idno type="wicri:Area/Main/Exploration">001E47</idno>
<idno type="wicri:Area/France/Extraction">000222</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study</title>
<author><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Nègre-Pagès">Laurence Nègre-Pagès</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>LN‐Pharma, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grandjean, Helene" sort="Grandjean, Helene" uniqKey="Grandjean H" first="Hélène" last="Grandjean">Hélène Grandjean</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U‐558, “Epidemiology and Public Health Analyses”, Faculty of Medicine, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fourrier, Annie" sort="Fourrier, Annie" uniqKey="Fourrier A" first="Annie" last="Fourrier">Annie Fourrier</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Inserm U‐657 “Pharmaco‐Épidémiology and Impact of Medicinal Product on Population” and Victor Segalen Bordeaux2, Pellegrin University, Bordeaux University Hospital, Bordeaux</wicri:regionArea>
<placeName><settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lepine, Jean Pierre" sort="Lepine, Jean Pierre" uniqKey="Lepine J" first="Jean Pierre" last="Lépine">Jean Pierre Lépine</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Fernand Widal Hospital, APHP, INSERM U 705 CNRS UMR 7157, Paris</wicri:regionArea>
<placeName><settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U‐825/CIC, Hôpital Purpan, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01-30">2010-01-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="157">157</biblScope>
<biblScope unit="page" to="166">166</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D9D631DF5FDF4A4D8385A38A41862796FC1B8E65</idno>
<idno type="DOI">10.1002/mds.22760</idno>
<idno type="ArticleID">MDS22760</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Antidepressive Agents (therapeutic use)</term>
<term>Anxiety (drug therapy)</term>
<term>Anxiety (epidemiology)</term>
<term>Anxiety (etiology)</term>
<term>Anxiety (physiopathology)</term>
<term>Cross-Sectional Studies</term>
<term>Depression (drug therapy)</term>
<term>Depression (epidemiology)</term>
<term>Depression (etiology)</term>
<term>Depression (physiopathology)</term>
<term>Female</term>
<term>France (epidemiology)</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson's disease</term>
<term>Prospective Studies</term>
<term>Questionnaires (standards)</term>
<term>Severity of Illness Index</term>
<term>Sex Factors</term>
<term>antidepressant</term>
<term>anxiety</term>
<term>anxiolytic</term>
<term>depression</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Antidepressive Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Anxiety</term>
<term>Depression</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Questionnaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Sectional Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Prospective Studies</term>
<term>Severity of Illness Index</term>
<term>Sex Factors</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Anxiety has been less extensively studied than depression in Parkinson's disease (PD). The DoPaMiP survey allowed assessing simultaneously anxiety and depressive symptoms in PD and comparing correlations of both symptoms with clinical and therapeutic features of the disease. Cross sectional survey conducted prospectively in 450 ambulatory nondemented PD patients and 98 patients with other disorders than PD. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), parkinsonism using the Unified Parkinson's Disease Rating Scale (UPDRS). Other clinical factors were measured using a structured standardized examination/questionnaire. The mean HADS‐A (anxiety) subscore was higher in PD patients than in the others (8.2 ± 3.9 vs. 6.5 ± 3.2, P < 10−4) as was the HADS‐D (depressive) subscore (6.6 ± 3.8 vs. 3.9 ± 3.2, P < 10−4). Patients with possible/probable anxious signs (HADS‐A ≥ 8) were more prevalent in PD (51% vs. 29%, P < 10−4) as were those with depressive symptoms (40% vs. 10%, P < 10−4). Conversely, anxiolytic and antidepressant medications consumption was not different between the 2 groups. Patients with anxious symptoms were more frequently female and younger than those without such symptoms, while those with depressive symptoms had more severe indices of parkinsonism, more comorbidities and lower cognitive function (Mini Mental State Exam). The logistic regression model revealed that patients with depressive symptoms received more frequently levodopa and less frequently a dopamine agonist. Anxiety and depressive symptoms were more frequent in PD patients than in medical control group. Both symptoms were commonly associated in the same PD patients, but were correlated with different clinical/therapeutic features, suggesting different underlying pathophysiological mechanisms. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
</region>
<settlement><li>Bordeaux</li>
<li>Paris</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Nègre-Pagès">Laurence Nègre-Pagès</name>
</noRegion>
<name sortKey="Fourrier, Annie" sort="Fourrier, Annie" uniqKey="Fourrier A" first="Annie" last="Fourrier">Annie Fourrier</name>
<name sortKey="Grandjean, Helene" sort="Grandjean, Helene" uniqKey="Grandjean H" first="Hélène" last="Grandjean">Hélène Grandjean</name>
<name sortKey="Lapeyre Estre, Maryse" sort="Lapeyre Estre, Maryse" uniqKey="Lapeyre Estre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<name sortKey="Lepine, Jean Pierre" sort="Lepine, Jean Pierre" uniqKey="Lepine J" first="Jean Pierre" last="Lépine">Jean Pierre Lépine</name>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name>
<name sortKey="Negre Ages, Laurence" sort="Negre Ages, Laurence" uniqKey="Negre Ages L" first="Laurence" last="Nègre-Pagès">Laurence Nègre-Pagès</name>
<name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name>
<name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000222 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000222 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:D9D631DF5FDF4A4D8385A38A41862796FC1B8E65
   |texte=   Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study

Anxious and depressive symptoms in Parkinson's disease: The French cross‐sectionnal DoPaMiP study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.